Trial Profile
Multicenter, Open-label, Randomized, Controlled, Parallel Arms Clinical Study on Performance of SGM-101, a Fluorochrome-labeled Anti-CEA Monoclonal Antibody, for Delineation of Primary/Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 29 Dec 2023
Price :
$35
*
At a glance
- Drugs SGM 101 (Primary)
- Indications Cancer metastases; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Diagnostic use; Registrational
- Sponsors SurgiMAb
- 04 May 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2023.
- 04 May 2022 Planned primary completion date changed from 1 Nov 2021 to 1 Nov 2023.
- 20 Oct 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.